Ergosterol Synthesis Inhibitors Market Size & Share, by Drug Type (Fluconazole, Miconazole, Itraconazole, Clotrimazole); Route of Administration (Topical, Oral); End-user (Pharmacy, Hospital) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 3111
  • Published Date: Sep 03, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Ergosterol Synthesis Inhibitors Market size is expected to expand at significant growth rate during the forecast period i.e., between 2024-2036. The growth of the market can be attributed to the increasing prevalence of fungal infections, especially in the tropical and sub-tropical regions in the world. Ergosterol is a compound present in the walls of fungal cells, which is essential for the viability of all fungi. Ergosterol synthesis inhibitors hamper the biosynthesis of this compound, which kills the fungi colony, therefore treating the infection. The demand for ergosterol synthesis inhibitors is estimated to grow on the back of its efficiency in alleviating fungal infections, including jock itch, ringworm, yeast infection, and dandruff. Moreover, lack of proper sanitization facilities and cleanliness in major parts of the world, is further expected to boost the market growth.


Global-Ergosterol-Synthesis-Inhibitors-Market-Overview
Get more information on this report: Request Free Sample PDF

Ergosterol Synthesis Inhibitors Sector: Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Fungal Infections
  • Lack of Proper Sanitization in Developing Nations

Challenges

  • Risk of Hepatotoxicity Caused by the Inhibitors
  • Availability of Generic Drugs in the Market

Ergosterol Synthesis Inhibitors Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
 
Get more information on this report: Request Free Sample PDF

Ergosterol Synthesis Inhibitors Segmentation

The global ergosterol synthesis inhibitors market is segmented by route of administration into topical, oral, and others, out of which, the topical segment is anticipated to hold the largest share in the market during the forecast period on account of ease of application, and higher effectiveness, as it directly targets the infection. On the basis of end-user, the market is segmented into pharmacy, hospital, and others. Out of these, the pharmacy segment is estimated to hold a notable share over the forecast period owing to the growing demand for over-the-counter inhibitors to cure fungal infections. 

Our in-depth analysis of the global ergosterol synthesis inhibitors market includes the following segments

 

By Drug Type

  • Fluconazole
  • Miconazole
  • Itraconazole
  • Clotrimazole
  • Others

 

By Route of Administration

  • Topical
  • Oral
  • Others

By End-User

 

  • Pharmacy
  • Hospitals
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Ergosterol Synthesis Inhibitors Industry - Regional Synopsis

APAC Market Statistics

Regionally, the global ergosterol synthesis inhibitors market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific is likely to dominate majority revenue share by 2036, on the back of rising prevalence of fungal infections, in tropical countries, such as, Indonesia, Thailand, and India. India witnessed 5 to 10 cases of fungal infection per 1,000 individuals, in 2019. The share in Thailand amounted 12-15 cases per 1000 individuals. Moreover, growing medical infrastructure and improving public healthcare system, backed by economic growth in the region, is estimated to boost the market growth.

Latin America Market Analysis

The ergosterol synthesis inhibitors market in the Latin America region is estimated to witness noteworthy growth over the forecast period, owing to the rising incidences of infections backed by the climatic conditions favorable for fungal infections, along with unavailability of proper sanitization and cleanliness is estimated to boost the market growth.

Research Nester
Global-Ergosterol-Synthesis-Inhibitors-Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Ergosterol Synthesis Inhibitors Landscape

    • SCYNEXIS, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Novartis AG
    • Kramer Laboratories, Inc.
    • Abbott Laboratories
    • Bayer AG
    • GlaxoSmithKline plc.
    • Glenmark Pharmaceuticals Limited
    • Merck & Co., Inc.
    • Astellas Pharma Inc.

In the News

  • April 30, 2021: SCYNEXIS announced the positive clinical outcomes of the investigational drug ibrexafungerp for vaginal yeast infections.
  • March 22, 2021:  Glenmark Pharmaceuticals Limited to join hands with Bausch Health Companies, Inc. for the market in Canada

Author Credits:  Radhika Pawar


  • Report ID: 3111
  • Published Date: Sep 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Ergosterol Synthesis Inhibitors Market size is expected to expand at significant growth rate during the forecast period i.e., between 2024-2036.

Recurring seasonal prevalence of influenza, coupled with government initiatives to curb the outbreak of influenza will boost the market growth.

Asia Pacific is likely to dominate majority revenue share by 2036, on the back of rising prevalence of fungal infections, in tropical countries, such as, Indonesia, Thailand, and India.

The major players in the market are Pfizer Inc., Novartis AG, Kramer Laboratories, Inc., Abbott Laboratories, Bayer AG, GlaxoSmithKline plc, and others.
Ergosterol Synthesis Inhibitors Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample